Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Crystallization (Commentary)

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 8 of 8
EC Number Crystallization (Commentary)
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21310 ns molecular dynamics simulations of inhibitor bound to isofrom AKR1C3. Binding could induce conformational changes to both inhibitor and enzyme. The compound presumably assumes a stable, energetically favored, planar conformation, with an estimated free energy of binding of -5 kcal/mol
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213docking of inhibitors (2E)-3-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid, (2E)-3-(4-ethylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid, (2E)-3-(4-bromophenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid and (2E)-3-[4-(methylsulfanyl)phenyl]-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid to crystal structure. Compounds occupy a similar position of the active site as the co-crystallized indomethacin, with the Aryl1 overlapping with the p-chlorobenzoyl moiety of the indomethacin and the Aryl2 overlapping with an indole part of the indomethacin
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213in complex with 3-phenoxybenzoic acid, to 1.68 A resolution, space group P212121
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213in complex with inhibitor 1-(4-[[(2R)-2-methylpiperidin-1-yl]sulfonyl]phenyl)-1,3-dihydro-2H-pyrrol-2-one. The 2-pyrrolidinone does not interact directly with residues in the oxyanion hole
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213in complex with inhibitor 3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid. Compound adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213purified enzyme with NADH, hanging drop vapour diffusion method, 4°C, in presence of 1.4 M ammonium sulfate, 0.14 M NaCl, and 0.1 M Tris, pH 9.0, rod cluster crystals appear within 1 week, X-ray diffraction structure determination and analysis at 1.8 A resolution, modeling
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213purified recombinant wild-type enzyme, hanging drop vapour diffusion method, 4°C, mixing of equal volumes of 14 mg/ml protein solution and mother liquor containing 0.1 M sodium citrate, pH 6.5, 0.1 M ammonium acetate, and 24-30% PEG 4000, cryoprotection of crystals in 20% ethylene glycol in mother liquor, X-ray diffraction structure determination and analysis at 1.9 A resolution, molecular replacement study
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.213vapor diffusion techniques using ammonium sulfate as precipitant
Results 1 - 8 of 8